Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2012 Results
Date:11/7/2012

/p>

-5 

Select Balance Sheet Data1 September 30June 30September 30(in thousands)201220122011Total cash and marketable securities

$ 134,404$ 144,701$ 180,459  

(1) Unaudited
(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTS
The tasimelteon Non-24 program continues towards the goal of a projected mid-2013 NDA filing with the FDA.  Vanda is in continuing discussions with the FDA to confirm the path and requirements for this regulatory submission, and while no agreement has been reached with the agency, the FDA has suggested that Vanda present its Non-24 study results to further the discussions.  The SET and RESET Phase III efficacy studies for Non-24 are both fully enrolled.  Vanda expects to report top-line results for the SET study by the end of 2012 and to report top-line results for the RESET study in the first quarter of 2013.In October 2012, Vanda announced that tasimelteon was shown for the first time to restore daily cortisol rhythms in totally blind patients suffering from Non-24.  Tasimelteon's effect has now been demonstrated on both melatonin and cortisol circadian rhythms, which further supports its potential to reset the master body clock.  This observation was made during an open-label screening segment of the RESET study.  Tasimelteon has the potential to be the first pharmaceutical product to address the circadian dyssynchrony which is definitional for Non-24.

The tasimelteon MAGELLAN Phase IIb/III efficacy study for MDD is fully enrolled and Vanda expects to report top-line results in the first quarter of 2013.  

The review of Vanda's Marketing Authorization Application for oral iloperidone tablets in the European Union is ongoing. Vanda is preparing for an expected oral hearing in November 2012 as it continues to evaluate its European strate
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
2. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
3. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
4. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Vanda Pharmaceuticals Reports First Quarter 2012 Results
9. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The Parenteral Drug Association (PDA) is moving ... protocols. The new initiative stems from ... industry participants and regulatory authority representatives at the PDA ... Washington, DC . Representatives of both the ... workshop. Attendees indicated openness to engaging regulators and industry ...
(Date:9/19/2014)... Calif. , Sept. 19, 2014 Today, iHealth ... capital from Xiaomi Ventures, Ltd. for its first institutional ... to continue expanding iHealth,s global reach, accelerate growth and ...  As part of the investment, Xiaomi Ventures will join ... areas of cloud infrastructure and ecommerce. "We ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/s6g5wm/global ) has announced the addition of ... report to their offering. ... devices have been broadly classified into wide ... are used for the treatment of different ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... New York, NY (PRWEB) September 19, 2014 ... by PR News at the Platinum PR and Top ... Grand Hyatt in New York City. Camino received honorable ... a Shoestring Campaign” — for its work elevating Latina ... with this incredible organization and be a part of ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 According ... manufacturers of the embattled blood-thinner Xarelto, named as defendants ... of Common Pleas, have moved the court to dismiss ... do not have sufficient connection with Philadelphia.* The cases ... et al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), ...
(Date:9/19/2014)... -- Although there is mounting evidence that muscle-strength ... older adults in the United States don,t engage ... research. Less than one-quarter of adults over ... Department of Health and Human Services, the study ... health and fitness and staying independent, researchers advised. ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , , MONDAY, May 19 (HealthDay News) -- Findings from two ... erectile dysfunction can be a powerful early warning sign for ... men with diabetes but no signs of heart disease found ... percent more likely to have a heart attack or other ...
... of Nebraska Medical Center-led pilot study that showed antidepressants ... and neck cancer patients is the focus of an ... one of the publications produced by the Journal of ... led by UNMCs William Lydiatt, M.D., and Bill Burke, ...
... study from University Hospitals Case Medical Center (UHCMC) finds ... with malignant brain tumors are not treated as aggressively ... Furthermore, the researchers find that if patients over 75 ... and radiation, they have better survival rates. The findings ...
... have new life as a stroke treatment, researchers say. ... ways inhibiting white blood cells and enzymes that, ... vessels, respectively, says Dr. David Hess, chair of the ... School of Medicine. The broad-spectrum antibiotic also seems to ...
... May 19 Baker Energy, a unit,of Michael ... that the Wyoming,State Department of Environmental Quality (DEQ) ... (Huber), with a first-of-its-kind award,for their joint commitment ... http://www.newscom.com/cgi-bin/prnh/20061214/BAKERLOGO ), Wyoming DEQ Storm ...
... a nationwide clinical trial led by a University of ... ablation is an effective treatment for dysplasia in people ... deadly gastrointestinal cancer. , The interim results show there ... and a placebo or sham treatment, said Dr. Nicholas ...
Cached Medicine News:Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 2Health News:Erectile Dysfunction a Strong Harbinger of Heart Trouble 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 2Health News:Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: